LDHA

Across TCGA pan-cancer cohorts, LDHA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LDHA data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LDHA mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LDHA expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

LUAD, CCRCC, and COAD are the cancer types where LDHA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.494	0.956	<.001	25	view →
CCRCC	DFS	Tertile	All	0.627	0.854	.010	10	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
UCEC	OS	Median	II,III,IV	1.000	0.638	.014	4	view →
HNSC	DFS	Median	III,IV	0.858	0.717	.046	1	view →
PDAC	DFS	Median	III,IV	0.492	0.833	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LDHA–LUAD (OS)

Open the LUAD breakdown →